DK Life Science Co., Ltd. (KOSDAQ:303810)

South Korea · Delayed Price · Currency is KRW

2,650.00

-100.00 (-3.64%)

Oct 8, 2026, 3:30 PM KST

Market Cap	84.76B -35.4%
Revenue (ttm)	117.75B -12.2%
Net Income	4.97B -38.2%
EPS	155.66 -38.6%
Shares Out	31.98M
PE Ratio	17.02
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	792,298
Open	2,740.00
Previous Close	2,750.00
Day's Range	2,650.00 - 2,780.00
52-Week Range	2,155.00 - 4,160.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About DK Life Science

DK Life Science Co., Ltd., a pharmaceutical company, develops and sells diagnostic medicines and medical devices in South Korea and internationally. It offers active pharmaceutical ingredients (API), injections, blood glucose self-monitoring device, Mobile CT equipment, and ultrasonic instruments. The company also offers catheters, MRI, CT scanner, ultrasound, mobile CT scanner, and X-ray equipment, as well as mammography image analysis assistance software. DK Life Science Co., Ltd. was founded in 2017 and is based in Seoul, South Korea. [Read more]

Industry Medical Instruments & Supplies

Sector Healthcare

Founded 2017

Employees 100

Stock Exchange KOSDAQ

Ticker Symbol 303810

Full Company Profile

Financial Performance

In 2025, DK Life Science's revenue was 130.34 billion, a decrease of -1.12% compared to the previous year's 131.82 billion. Earnings were 8.66 billion, an increase of 285.71%.

Financial Statements